Welcome to our dedicated page for Moolec Science SA SEC filings (Ticker: MLECW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Moolec Science SA’s warrants (MLECW) provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents cover the activities of Moolec Science, a science-based ingredient company focused on producing animal proteins in plants through Molecular Farming, and offer detailed insight into its corporate structure, transactions, and financial reporting.
Investors can review Form 20-F annual reports for audited consolidated financial statements of Moolec Science SA, along with discussions of its Molecular Farming technology, alternative protein ingredient focus, and risk factors. Interim information is available through Form 6-K filings, which Moolec uses to furnish unaudited financial statements, pro forma financial information, and updates on significant corporate events.
A notable Form 6-K describes a ten-to-one reverse stock split of Moolec Science (Luxembourg) ordinary shares and the subsequent redomiciliation to the Cayman Islands, where the company continues as Moolec Science (Cayman Islands). The same filing explains a business combination agreement with Bioceres Group Limited, Gentle Technologies Corp, and Nutrecon LLC, under which Moolec became the legal parent of the combined group while Bioceres Group Limited is treated as the accounting acquirer under IFRS 3.
That Form 6-K also discusses changes in control at Bioceres Crop Solutions Corp., debt defaults and restructuring processes at Bioceres S.A. and Bioceres LLC, and states that these events raise a material uncertainty that may cast significant doubt about the ability of the Bioceres Group and Moolec Science to continue as a going concern. The filing notes that the consolidated financial statements do not include adjustments that might result from this uncertainty.
On this page, Stock Titan pairs these filings with AI-powered summaries that explain the key points of lengthy documents such as 20-F annual reports and 6-K current reports. Users can quickly understand reverse stock split mechanics, jurisdiction changes, business combinations, and going concern disclosures without reading every page. Real-time updates from EDGAR ensure that new Moolec Science filings, including those related to the MLECW warrants, appear promptly with concise explanations to support investor research.
Moolec Science filed a Form 6-K to share the notice of its virtual Annual General Meeting of shareholders. The AGM will be held on May 13, 2026 at 9:00 a.m. Eastern Time.
Shareholders will vote on three proposals: approval of the consolidated financial statements for the year ended June 30, 2025, re-election of four directors (Daniel Core, Diego Abelleyra Llodra, Oscar Leon Bentancor and Romualdo Varela), and re-appointment of Price Waterhouse & Co. S.R.L. as independent registered public accounting firm for the fiscal year ending June 30, 2026.
Holders of shares as of the April 6, 2026 record date are eligible to vote, primarily by submitting proxies by May 11, 2026 at 11:59 p.m. Eastern time. The meeting will be conducted virtually via a dedicated hosting page with telephone listen-only access.
Moolec Science filed a Form 6-K to share the notice of its virtual Annual General Meeting of shareholders. The AGM will be held on May 13, 2026 at 9:00 a.m. Eastern Time.
Shareholders will vote on three proposals: approval of the consolidated financial statements for the year ended June 30, 2025, re-election of four directors (Daniel Core, Diego Abelleyra Llodra, Oscar Leon Bentancor and Romualdo Varela), and re-appointment of Price Waterhouse & Co. S.R.L. as independent registered public accounting firm for the fiscal year ending June 30, 2026.
Holders of shares as of the April 6, 2026 record date are eligible to vote, primarily by submitting proxies by May 11, 2026 at 11:59 p.m. Eastern time. The meeting will be conducted virtually via a dedicated hosting page with telephone listen-only access.
Moolec Science SA director Daniel Joaquin Core filed a Form 3 reporting existing equity awards rather than any new share purchases or sales. He reports direct holdings of options over 934 ordinary shares at an exercise price of $7.14 expiring on June 30, 2031, plus separate option holdings over 933 shares expiring on June 30, 2032 and another 933 shares expiring on June 30, 2033.
Moolec Science SA director Daniel Joaquin Core filed a Form 3 reporting existing equity awards rather than any new share purchases or sales. He reports direct holdings of options over 934 ordinary shares at an exercise price of $7.14 expiring on June 30, 2031, plus separate option holdings over 933 shares expiring on June 30, 2032 and another 933 shares expiring on June 30, 2033.
Agriculture Investment Group Corp. became the controlling shareholder of Moolec Science SA by converting preference shares into ordinary shares. It now beneficially owns 1,354,186 ordinary shares, representing 65.1% of Moolec’s outstanding ordinary shares. Total ordinary shares outstanding were 2,080,304 as of January 5, 2026.
The conversion followed a $5,473,425 aggregate amount of preference shares being exchanged for ordinary shares under a Subscription Agreement originally dated December 9, 2024 and later amended. Agriculture Investment Group now has sole voting and dispositive power over its entire Moolec stake.
Agriculture Investment Group Corp. became the controlling shareholder of Moolec Science SA by converting preference shares into ordinary shares. It now beneficially owns 1,354,186 ordinary shares, representing 65.1% of Moolec’s outstanding ordinary shares. Total ordinary shares outstanding were 2,080,304 as of January 5, 2026.
The conversion followed a $5,473,425 aggregate amount of preference shares being exchanged for ordinary shares under a Subscription Agreement originally dated December 9, 2024 and later amended. Agriculture Investment Group now has sole voting and dispositive power over its entire Moolec stake.
Agriculture Investment Group Corp. became the controlling shareholder of Moolec Science SA, reporting beneficial ownership of 1,354,186 ordinary shares, or 65.1% of the company, after converting preference shares into ordinary shares under a prior subscription agreement.
The ownership percentage is based on 2,080,304 ordinary shares outstanding as of January 5, 2026. Agriculture Investment Group Corp. holds sole voting and dispositive power over its shares and states it may review and change its intentions toward Moolec Science over time.
Agriculture Investment Group Corp. became the controlling shareholder of Moolec Science SA, reporting beneficial ownership of 1,354,186 ordinary shares, or 65.1% of the company, after converting preference shares into ordinary shares under a prior subscription agreement.
The ownership percentage is based on 2,080,304 ordinary shares outstanding as of January 5, 2026. Agriculture Investment Group Corp. holds sole voting and dispositive power over its shares and states it may review and change its intentions toward Moolec Science over time.
Moolec Science reports a change in control after Agriculture Investment Group Corp. (AIGC) became its controlling shareholder. On April 1, 2026, AIGC held 65.1% of Moolec’s outstanding shares following a partial conversion of its preference shares into ordinary shares under an existing subscription agreement. As a foreign private issuer, Moolec has chosen to follow home country practice instead of Nasdaq’s usual requirement for prior shareholder approval in transactions that result in a change of control.
Moolec Science reports a change in control after Agriculture Investment Group Corp. (AIGC) became its controlling shareholder. On April 1, 2026, AIGC held 65.1% of Moolec’s outstanding shares following a partial conversion of its preference shares into ordinary shares under an existing subscription agreement. As a foreign private issuer, Moolec has chosen to follow home country practice instead of Nasdaq’s usual requirement for prior shareholder approval in transactions that result in a change of control.
Moolec Science SA Chief Financial Officer Valeria Ines Falottico filed an initial insider ownership report listing her holdings in the company’s ordinary shares and equity awards. She directly holds 891 ordinary shares.
The filing also lists share options over 2,222 ordinary shares at an exercise price of $7.14 per share, with expiration dates in 2031, 2032, and 2033. In addition, she holds restricted share unit awards linked to 2,333 underlying ordinary shares at $14.28 per share and 2,333 underlying ordinary shares at $28.56 per share, both expiring in 2031.
Moolec Science SA Chief Financial Officer Valeria Ines Falottico filed an initial insider ownership report listing her holdings in the company’s ordinary shares and equity awards. She directly holds 891 ordinary shares.
The filing also lists share options over 2,222 ordinary shares at an exercise price of $7.14 per share, with expiration dates in 2031, 2032, and 2033. In addition, she holds restricted share unit awards linked to 2,333 underlying ordinary shares at $14.28 per share and 2,333 underlying ordinary shares at $28.56 per share, both expiring in 2031.
Moolec Science SA director Lorenzo Varela has filed a Form 3 reporting his initial beneficial ownership in the company. The filing shows three direct option-based positions over ordinary shares, each with a $7.14 exercise price and expirations in 2031, 2032, and 2033.
The underlying options cover 934, 933, and 933 ordinary shares, respectively, and are structured as share options rather than open-market share purchases or sales. The disclosure is administrative, establishing his baseline holdings without reporting any new buy or sell transactions.
Moolec Science SA director Lorenzo Varela has filed a Form 3 reporting his initial beneficial ownership in the company. The filing shows three direct option-based positions over ordinary shares, each with a $7.14 exercise price and expirations in 2031, 2032, and 2033.
The underlying options cover 934, 933, and 933 ordinary shares, respectively, and are structured as share options rather than open-market share purchases or sales. The disclosure is administrative, establishing his baseline holdings without reporting any new buy or sell transactions.
Moolec Science SA filed an initial insider holdings report for Chief Technology Officer Paola Alexandra Diaz Dellavalle. She holds share options over 934 ordinary shares at an exercise price of 7.1400 per share expiring on June 30, 2031, and additional options over 933 shares each expiring on June 30, 2032 and June 30, 2033. These entries reflect her option-based equity position rather than new share purchases or sales.
Moolec Science SA filed an initial insider holdings report for Chief Technology Officer Paola Alexandra Diaz Dellavalle. She holds share options over 934 ordinary shares at an exercise price of 7.1400 per share expiring on June 30, 2031, and additional options over 933 shares each expiring on June 30, 2032 and June 30, 2033. These entries reflect her option-based equity position rather than new share purchases or sales.
Moolec Science SA director Abelleyra Llodra Diego Juan has filed a Form 3 reporting direct holdings of share options over ordinary shares. The filing lists three option grants covering 934, 933 and 933 underlying ordinary shares at an exercise price of 7.1400, expiring on 2031-06-30, 2032-06-30 and 2033-06-30. These entries describe existing derivative positions rather than new open‑market purchases or sales.
Moolec Science SA director Abelleyra Llodra Diego Juan has filed a Form 3 reporting direct holdings of share options over ordinary shares. The filing lists three option grants covering 934, 933 and 933 underlying ordinary shares at an exercise price of 7.1400, expiring on 2031-06-30, 2032-06-30 and 2033-06-30. These entries describe existing derivative positions rather than new open‑market purchases or sales.
Moolec Science SA filed an initial ownership report for Chief Executive Officer Alejandro Carlos Antalich, detailing his equity-based awards in ordinary shares. The filing lists share options for 3,334, 3,333 and 3,333 underlying shares at an exercise price of $7.1400, expiring between 2031 and 2033.
It also shows restricted share units linked to 6,667 and 6,666 underlying ordinary shares at exercise prices of $14.2800 and $28.5600, expiring on February 6, 2031. These entries describe existing awards and do not reflect new open-market purchases or sales.
Moolec Science SA filed an initial ownership report for Chief Executive Officer Alejandro Carlos Antalich, detailing his equity-based awards in ordinary shares. The filing lists share options for 3,334, 3,333 and 3,333 underlying shares at an exercise price of $7.1400, expiring between 2031 and 2033.
It also shows restricted share units linked to 6,667 and 6,666 underlying ordinary shares at exercise prices of $14.2800 and $28.5600, expiring on February 6, 2031. These entries describe existing awards and do not reflect new open-market purchases or sales.